| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,775 | -1,241 |
| Depreciation | 72 | 36 |
| Stock-based compensation | 96 | 57 |
| Deferred tax asset | -141 | - |
| Operating lease right-of-use asset | 392 | 448 |
| Accounts receivable, net | 294 | 216 |
| Inventories, net | 444 | 652 |
| Deferred income tax expense | - | -93 |
| Prepaid expenses and other current assets | 834 | 819 |
| Deferred consideration, net of discount | 114 | 55 |
| Accounts payable | 360 | 1,026 |
| Accrued expenses and other current liabilities | -326 | -484 |
| Withholding tax payable | 214 | 104 |
| Operating lease liabilities | 392 | 448 |
| Deferred revenue | 26 | 26 |
| Net cash used in operating activities | -2,650 | -2,015 |
| Purchases of property and equipment | 116 | 106 |
| Net cash used in investing activities | -116 | -106 |
| Proceeds from issuance of common stock, net of offering expenses | 0 | 0 |
| Proceeds from exercise of employee stock options | 44 | 23 |
| Payments for fractional shares related to reverse-split | 0 | - |
| Principal payments on short-term debt | 164 | 81 |
| Net cash (used in) provided by financing activities | -120 | -58 |
| Effect of exchange rate on cash and cash equivalents | 547 | 410 |
| Net (decrease) increase in cash and cash equivalents | -2,339 | -1,769 |
| Cash and cash equivalents at beginning of period | 5,374 | - |
| Cash and cash equivalents at end of period | 3,035 | - |
Sonoma Pharmaceuticals, Inc. (SNOA)
Sonoma Pharmaceuticals, Inc. (SNOA)